Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Company profile
Ticker
BHC
Exchange
Website
CEO
J. Michael Pearson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIOVAIL Corp, BIOVAIL CORP INTERNATIONAL, BIOVAIL CORPORATION INTERNATIONAL, Valeant Pharmaceuticals International, Inc.
SEC CIK
Corporate docs
Subsidiaries
Bausch & Lomb Argentina S.R.L. • Waicon Vision S.A. • Bausch & Lomb (Australia) Pty Limited • Bausch Health Australia Pty Limited • Wirra Holdings Pty Limited • Bausch & Lomb Australia Holdings Pty Limited • Solta Medical Australia Pty Limited • BAUSCH HEALTH LLC • Bausch & Lomb Pharma S.A. • PharmaSwiss BH Društvo za trgovinu na veliko d.o.o. ...
BHC stock data
News
Bausch Health to Appeal XIFAXAN Patent Decision to U.S. Court of Appeals for the Federal Circuit, Says Expects Decision To Issue Within 12-18 Months
10 Aug 22
Bausch Health Companies Shares Move Higher; Traders Circulate District Court Opinion Ruling In Favor Of Bausch Health In Xifaxan Oral Case
10 Aug 22
BMO Capital Maintains Market Perform on Bausch Health Companies, Lowers Price Target to $8
10 Aug 22
RBC Capital Maintains Sector Perform on Bausch Health Companies, Lowers Price Target to $4.5
10 Aug 22
Recap: Bausch Health Companies Q2 Earnings
9 Aug 22
Press releases
Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit
10 Aug 22
Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)
10 Aug 22
BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS
9 Aug 22
Thinking about buying stock in Toughbuilt Industries, Exela Technologies, Bausch Health, Fluence Energy, or Evofem Biosciences?
29 Jul 22
Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation
28 Jul 22
Analyst ratings and price targets
Current price
Average target
$8.17
Low target
$4.50
High target
$12.00
BMO Capital
Maintains
$8.00
RBC Capital
Maintains
$4.50
JP Morgan
Maintains
$12.00
Calendar
10 May 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.46B | 2.46B | 2.46B | 2.46B | 2.46B | 2.46B |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | (no burn) | 21M | (no burn) |
Cash used (since last report) | n/a | n/a | n/a | n/a | 92.4M | n/a |
Cash remaining | n/a | n/a | n/a | n/a | 2.37B | n/a |
Runway (months of cash) | n/a | n/a | n/a | n/a | 112.7 | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Jun 22 | Schutter Richard U De | Common Shares, No Par Value | Grant | Acquire A | No | No | 8.36 | 4,111 | 34.37K | 359,590 |
30 Jun 22 | Brett Icahn | Common Shares, No Par Value | Grant | Acquire A | No | No | 8.36 | 3,663 | 30.62K | 51,157 |
30 Jun 22 | Steven D Miller | Common Shares, No Par Value | Grant | Acquire A | No | No | 8.36 | 3,663 | 30.62K | 101,279 |
30 Jun 22 | Wechsler Amy B | Common Shares, No Par Value | Grant | Acquire A | No | No | 8.36 | 822 | 6.87K | 134,563 |
30 Jun 22 | Robertson Russel C | Common Shares, No Par Value | Grant | Acquire A | No | No | 8.36 | 4,560 | 38.12K | 167,200 |
Institutional ownership, Q1 2022
0.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 31.84M |
Total shares | 1.39M |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bruce & Co. | 1.38M | $31.56M |
LeJeune Puetz Investment Counsel | 12.39K | $283K |
Financial report summary
?Competition
Akorn • Staar Surgical • IRIDEX • Prestige Consumer Healthcare • EyePoint Pharmaceuticals • LENSAR • Albireo Pharma • Aerie Pharmaceuticals • Kiora Pharmaceuticals • Aquestive TherapeuticsRisks
- As a result of the current conflict between Russia and Ukraine, including the recent invasion of Ukraine by Russia, the current and any future responses by the global community to such conflict and any counter responses by the Russian government or other entities or individuals, and the potential expansion of the conflict to other countries, we have begun to experience and may continue to experience an adverse impact on our business and operations in this region, as well as on our business and operations generally, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares to decline.
Management Discussion
- Revenues for 2021 and 2020 were $8,434 million and $8,027 million, respectively, an increase of $407 million, or 5%. The increase was primarily driven by: (i) a net increase in volumes and (ii) the favorable impact of foreign currencies, primarily in Europe, Asia and Canada. These increases were partially offset by: (i) our divestiture of Amoun on July 26, 2021 and (ii) a decrease in net realized pricing. The net increase in volumes was primarily due to the positive impacts from the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, primarily during the three months ended June 30, 2021, partially offset by the impact of the loss of exclusivity of certain products. The changes in our segment revenues and segment profits are discussed in further detail in the subsequent section titled “Reportable Segment Revenues and Profits”.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abeyance, affiliate, agricultural, Apotex, banc, bankruptcy, benchmark, BLCO, bromide, buy, Cal, CDOR, cease, chapter, closer, CODM, commodity, community, conference, counter, counteractive, cyber, cybersecurity, cyberterrorism, Czech, damage, dealt, Dexamethasone, disconnect, discontent, displacement, divisional, doubt, Dutch, en, energy, EU, EURIBOR, exacerbating, facilitate, faith, fleeing, flexibility, Flunisolide, gas, gave, geopolitical, hampered, hepatology, hinder, hryvnia, humanitarian, IG, imposition, inadequate, inception, increasingly, installation, installment, Interntaional, invaded, invasion, Irish, irrevocably, JJCI, knowledge, Latanoprost, LIBOR, LTL, Lupin, mediate, mediation, Mellon, merger, methynaltrexone, military, network, notch, Notwithstanding, oil, omicron, overseeing, perpetrated, piped, popular, practice, precise, preclude, proactively, promptly, protracted, provoked, refundable, registration, rehearing, Remainco, repatriation, reply, Republic, retaliatory, ruble, Russia, Russian, satisfaction, Shanghai, shelter, sixty, skincare, Slovakia, SOFR, solicitation, Somerset, SONIA, StableVisc, sterling, stoppage, substantive, subvariant, surge, suspend, suspended, talc, taxation, thereunder, ticker, Tobramycin, traffic, trail, transitional, trustee, UK, Ukraine, Ukrainian, unavailability, underwriting, undrawn, unforeseen, Uniform, unrestricted, unwind, unwinding, unwound, vii, viii, voidable, war, Western, WHA, wholly, wider, worse, worsen
Removed:
accessed, actinic, adenylate, Adjudication, Allegro, anemia, angiogenic, antihistamine, appointed, Appointment, ASS, atopic, bill, biopharmaceutical, Bisocard, bolt, bottom, BP, calculating, channel, classified, combined, commencement, complexity, compliant, consumption, Contrave, cyclase, defer, Departure, derivative, developing, Diastat, distributing, doctor, duty, Espaven, Eton, evidence, exceed, expanding, expensed, expensive, experiencing, exploring, FASB, fatty, feet, fiduciary, field, financed, forced, fumarate, funding, gradual, Graham, greatest, hiring, home, House, idling, impactful, implicated, initiation, insulated, integrin, interaction, intraperiod, Italy, Ivexterm, Jan, ketotifen, launching, led, Los, Luminate, measuring, metabolic, methodology, metric, Milan, minimizing, mitochondrial, moving, Mysimba, NAFLD, NASH, necessitate, NeutraSal, nonalcoholic, notably, operation, Ophtho, originated, performing, pituitary, postponement, postponing, preferred, prepay, preservative, prioritization, prioritize, privately, progressed, Prolensa, promoted, purportedly, readily, realigned, rebalancing, reenacting, relieve, remained, reopening, responded, retina, revising, risuteganib, room, separately, simultaneously, site, slower, spot, statue, steeper, Stockholder, targeting, thirty, Thrombo, translate, travel, unfavorably, University, VBP, Vice, warning, waste, yield
Financial reports
Current reports
8-K
Bausch Health Announces Second-quarter 2022 Results
9 Aug 22
8-K
Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation
29 Jul 22
8-K
Regulation FD Disclosure
20 Jul 22
8-K
Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors
23 Jun 22
8-K
Departure of Directors or Certain Officers
23 Jun 22
8-K
Agenda 2 3 4 1 Call to order Procedural matters Voting items and results Management presentation 5 Q&A
21 Jun 22
8-K
Departure of Directors or Certain Officers
3 Jun 22
8-K
Departure of Directors or Certain Officers
31 May 22
8-K
Other Events
10 May 22
8-K
Bausch Health and Bausch + Lomb Corporation Announce Closing of Initial Public Offering of Bausch + Lomb and Related Debt Transactions
10 May 22
Registration and prospectus
S-8
Registration of securities for employees
7 May 20
S-8
Registration of securities for employees
10 Aug 18
S-3ASR
Automatic shelf registration
1 Mar 18
SC TO-T/A
Third party tender offer statement (amended)
14 Oct 15
SC TO-T/A
Third party tender offer statement (amended)
8 Oct 15
SC TO-T/A
Third party tender offer statement (amended)
4 Oct 15
SC TO-T/A
Third party tender offer statement (amended)
4 Oct 15
SC TO-T/A
Third party tender offer statement (amended)
29 Sep 15
SC TO-T/A
Third party tender offer statement (amended)
28 Sep 15
SC TO-T/A
Third party tender offer statement (amended)
17 Sep 15
Proxies
DEFA14A
Additional proxy soliciting materials
15 Jun 22
DEFA14A
Additional proxy soliciting materials
2 May 22
DEFA14A
Additional proxy soliciting materials
1 Apr 21
DEFA14A
Additional proxy soliciting materials
18 Mar 21
DEFA14A
Additional proxy soliciting materials
10 Apr 20
DEFA14A
Additional proxy soliciting materials
2 Apr 20
DEFA14A
Additional proxy soliciting materials
16 Mar 20
DEF 14A
Definitive proxy
16 Mar 20
Other
SD
Conflict minerals disclosure
2 Jun 22
SD
Conflict minerals disclosure
24 Jun 21
SD
Conflict minerals disclosure
1 Jun 20
UPLOAD
Letter from SEC
15 Sep 19
CORRESP
Correspondence with SEC
21 Aug 19
UPLOAD
Letter from SEC
7 Aug 19
SD
Conflict minerals disclosure
5 Jun 19
CT ORDER
Confidential treatment order
14 Mar 19
SD
Conflict minerals disclosure
8 Jun 18
SD
Conflict minerals disclosure
30 May 17
Ownership
4/A
Bausch Health Companies / RUSSEL C ROBERTSON ownership change
6 Jul 22
4
Bausch Health Companies / John Paulson ownership change
5 Jul 22
4
Bausch Health Companies / RUSSEL C ROBERTSON ownership change
5 Jul 22
4
Bausch Health Companies / AMY B WECHSLER ownership change
5 Jul 22
4
Bausch Health Companies / Steven D Miller ownership change
5 Jul 22
4
Bausch Health Companies / BRETT ICAHN ownership change
5 Jul 22
4
Bausch Health Companies / SCHUTTER RICHARD U DE ownership change
5 Jul 22
4
Bausch Health Companies / SARAH B KAVANAGH ownership change
28 Jun 22
4
Bausch Health Companies / Steven D Miller ownership change
28 Jun 22
4
Bausch Health Companies / John Paulson ownership change
28 Jun 22
Patents
Utility
Water Extractable Ophthalmic Devices
11 Aug 22
A water extractable ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) one or more cyclic lactams; (b) one or more non-bulky organosilicon-containing monomers; (c) one or more bulky siloxane monomers; and (d) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group.
Design
Access device
2 Aug 22
Inventors: Craig Bockenstedt, Richard Malwitz, Adam Weisgerber, Jeffrey Ladwig, Aaron Piazza, Michael Carl Beckman
Utility
Encrypted memory device
2 Aug 22
In one implementation, a system for detecting counterfeit accessories that are consumable, disposable, or otherwise user replaceable is disclosed.
Utility
Topical Compositions and Methods for Treating Skin Diseases
28 Jul 22
Topical pharmaceutical compositions include tazarotene or a pharmaceutically acceptable salt of tazarotenic acid and an oil-in-water emulsion vehicle that forms a lotion.
Design
Light therapy device
26 Jul 22
Inventors: Craig Bockenstedt, Richard Malwitz, Adam Weisgerber, Jeffrey Ladwig, Aaron Piazza, Michael Carl Beckman
Transcripts
2022 Q2
Earnings call transcript
9 Aug 22
2022 Q1
Earnings call transcript
10 May 22
2021 Q4
Earnings call transcript
23 Feb 22
2021 Q3
Earnings call transcript
2 Nov 21
2021 Q2
Earnings call transcript
3 Aug 21
2021 Q1
Earnings call transcript
4 May 21
2020 Q4
Earnings call transcript
24 Feb 21
2020 Q3
Earnings call transcript
3 Nov 20
2020 Q3
Earnings call transcript
3 Nov 20
2020 Q3
Earnings call transcript
3 Nov 20
Reddit threads
Can anyone tell me why a companies market cap could be 20% of its enterprise value
10 Aug 22
(8/9) Tuesday's Pre-Market Stock Movers & News
9 Aug 22
Daily Discussion Thread - August 9th, 2022
9 Aug 22
Buckle up your nuts
31 Jul 22
Jimmy Cramer doing what he does best! Tanking $BHC -50%
28 Jul 22
Daily Discussion Thread for July 28, 2022
28 Jul 22
Daily Discussion Thread for June 24, 2022
24 Jun 22
BHC spun off BLOC, where are my shares?
22 Jun 22
Thoughts on BHC and BLCO? Here's where I'm at...
21 May 22
Daily Discussion Thread - May 10th, 2022
10 May 22